A Phase I Trial of Panobinostat (LBH589) and Epirubicin in Patients With Solid Tumor Malignancies.
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Epirubicin (Primary) ; Panobinostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2016 Status changed from active, no longer recruiting to completed, according to results published in the Annals of Oncology.
- 12 Feb 2016 Results published in the Annals of Oncology
- 18 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.